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Early-adulthood body size is strongly inversely associated with risk of premenopausal breast cancer. It is unclear whether
subsequent changes in weight affect risk. We pooled individual-level data from 17 prospective studies to investigate the
association of weight change with premenopausal breast cancer risk, considering strata of initial weight, timing of weight
change, other breast cancer risk factors and breast cancer subtype. Hazard ratios (HR) and 95% confidence intervals (CI) were
obtained using Cox regression. Among 628,463 women, 10,886 were diagnosed with breast cancer before menopause. Models
adjusted for initial weight at ages 18–24 years and other breast cancer risk factors showed that weight gain from ages 18–24
to 35–44 or to 45–54 years was inversely associated with breast cancer overall (e.g., HR per 5 kg to ages 45–54: 0.96, 95%
CI: 0.95–0.98) and with oestrogen-receptor(ER)-positive breast cancer (HR per 5 kg to ages 45–54: 0.96, 95% CI: 0.94–0.98).
Weight gain from ages 25–34 was inversely associated with ER-positive breast cancer only and weight gain from ages 35–44
was not associated with risk. None of these weight gains were associated with ER-negative breast cancer. Weight loss was not
consistently associated with overall or ER-specific risk after adjusting for initial weight. Weight increase from early-adulthood
to ages 45–54 years is associated with a reduced premenopausal breast cancer risk independently of early-adulthood weight.
Biological explanations are needed to account for these two separate factors.
What’s new?
Body weight in childhood and early adulthood plays a key role in determining premenopausal breast cancer risk but little is
conclusively known about how subsequent weight changes affect this risk. Here the authors pooled results from existing
studies on weight changes and breast cancer risk including more than 600,000 premenopausal women. The results show that
weight gain >10–15 kg from early adulthood on lowers the risk of developing premenopausal breast cancer, providing further
evidence of body weight as an important determinant of breast cancer risk.
Introduction
The influence of obesity on breast cancer risk varies by life-
stage. Adiposity before menopause is inversely associated with
risk, whereas adiposity during the postmenopausal years is
positively associated with risk.1–3 The inverse association with
premenopausal adiposity is particularly strong for adiposity in
early adulthood, that is, ages 18–24 years,4 and it is likely that
the origin of this association lies in childhood.5,6
It is not clear whether changes in weight after early adult-
hood further affect risk of premenopausal breast cancer. The
role of weight gain in adulthood is of interest because increases
in body weight during adulthood mostly reflect accumulation of
adipose rather than lean tissue, and therefore any change might
reflect body fatness better than adult weight itself, and because
of its association with intra-abdominal fat deposition, which is
more metabolically active than peripheral adiposity.7 Timing of
weight change might additionally be relevant in that weight
change at different stages of life, for example, during periods of
hormonal change such as during pregnancy, might have differ-
ent biological effects and differentially affect breast cancer risk.8
Due to the relatively low incidence of premenopausal breast
cancer, past studies have had limited numbers of cases to inves-
tigate the association of weight change with risk by timing of
weight change, to examine the effect of weight loss or to analyse
these associations by participant or tumour characteristics.
Additionally, past studies have often only used proxies for
menopausal status, such as status at study entry or attained age,
rather than time-updated menopausal status.
We pooled individual-level data from prospective studies
to investigate the association of weight change and its timing
with premenopausal breast cancer risk, overall and by breast
cancer characteristics.
Materials and Methods
We used data from 17 of the 22 cohort studies in the
Premenopausal Breast Cancer Collaborative Group9 that had
participants’ weight available at a minimum of two time
points before women were age 55 years and had at least
100 breast cancer cases diagnosed before age 55 years.
Individual-level data were pooled from cohorts in North
America (n = 9), Europe (n = 6), Asia (n = 1) and Australia
(n = 1), with participants recruited between 1963 and 2013.
Data from 1 to 16 questionnaire rounds per study were
harmonised to a common protocol. Women provided histori-
cal information on their weight prior to study entry on the
baseline questionnaire and their current body weight was pro-
vided or measured at baseline and on follow-up question-
naires (if available). This work was approved by the relevant
institutional review boards and women provided informed
consent to partake.
Women were included in the analysis if they were breast
cancer-free and premenopausal at study entry, and had
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premenopausal weight available for at least two age categories
(defined below). Premenopausal follow-up time was deter-
mined from menopause information obtained from multiple
questionnaire rounds, and, if missing, assumptions based on
attained age using age 50 as cut-off (Supporting Information).
The main analytical endpoint was diagnosis with invasive
or in situ premenopausal breast cancer combined. We also
conducted analyses of invasive and in situ outcomes sepa-
rately, as well as outcomes by hormone-receptor status and a
clinicopathological surrogate definition of intrinsic breast can-
cer subtypes (Supporting Information).
Analyses were conducted using STATA 14.2.10 Data on
weight was available at 2–13 time points per study. We first
investigated weight patterns across time with longitudinal trajec-
tory models at a selected number of time points11 (Supporting
Information Figs. S1 and S2). These models resulted in trajecto-
ries of weight gain delineated by initial weight, but did not delin-
eate women with weight loss as a separate group. We therefore
instead constructed variables for weight change between the age
categories 18–24, 25–34, 35–44 and 45–54 years, to be able to
use data from all the studies with varying numbers of time
points and to examine the association of weight loss with risk.
Weight at ages 18–24 was derived, for the great majority of sub-
jects, from weight at age 18 or 20 (depending on the study) ret-
rospectively reported on the baseline questionnaire. Weight at
other ages was usually reported or measured at or after recruit-
ment to the study.
Follow-up for breast cancer began at the second weight
assessment that was used to compute weight change, or at
recruitment, whichever was later. Follow-up ended with the first
of the following events: breast cancer diagnosis, menopause, last
follow-up, death or age 55 years. Hazard ratios (HR) and 95%
confidence intervals (CI) representing estimates of relative risk
of breast cancer were derived from Cox proportional hazards
models with attained age as the underlying time scale.12 Models
were adjusted for cohort, year of birth, age at menarche, parity,
age at first birth, time since most recent birth, adult height at
recruitment and family history of breast cancer. Covariate infor-
mation was updated over follow-up, where available. In the
main analyses, we analysed weight change in categories of 5.0 kg
increments and as linear trends in risk per 5.0 kg of weight gain.
We also obtained results in finer strata of 2.5 kg increments
(Supporting Information). We obtained HRs for weight change
with and without adjustment for starting weight to investigate
whether starting weight was a confounder, but presented results
adjusted for starting weight unless otherwise stated.
Tests for effect modification of weight change by cohort,
starting weight, other available breast cancer risk factors and
time since weight change were conducted using log-likelihood
ratio tests.13 We estimated separate risk-factor associations for
breast cancer type-specific outcomes using an augmentation
method.14
We conducted sensitivity analyses by (i) excluding the
first 2 years of follow-up to reduce the chance of reverse
causation by preclinical disease; (ii) restricting analyses to
reported, rather than assumed, premenopausal follow-up
time; (iii) repeating the analyses excluding one study at a
time; (iv) additionally adjusting for the number of years
between weight assessments; (v) in analyses restricted to
subjects with weight at ages 18–24 available, adjusting for
weight at ages 18–24 rather than weight at the start of the
age category; (vi) restricting analyses to the five cohorts
contributing to analyses of weight change at all of the six
age groups; (vii) repeating analyses for subjects with non-
missing covariate information; (viii) for subjects with avail-
able data, additionally adjusting one at a time for variables
only available for some cohorts: ethnicity, cigarette smoking,
alcohol consumption, physical activity level, polycystic ovary
syndrome, childhood somatotype and mammographic
screening history.
We additionally analysed the average annual weight change
assuming a linear trajectory as a risk factor, rather than an
absolute increase in weight.
Data availability
Research data will be made available upon reasonable request
due to privacy/ethical restrictions.
Results
The analyses included 628,463 women, whose median age at
recruitment was 39.4 (interquartile range 33.8–44.0) years and
who were followed for a median of 10.1 (interquartile range
5.9–15.5) years from recruitment during which 10,886 breast
cancer cases (8,509 invasive) were diagnosed. Oestrogen-
receptor (ER) status was known for 6,994 (72.5% of invasive
and 43.5% of in situ) breast cancer patients; ER, progesterone-
receptor (PR) and HER2-status was available for 3,425 (37.2%
invasive, 13.9% in situ) breast cancer patients.
Most women were white (85.7%), from North America
(56.6%), or Europe (41.1%) (Table 1). Women in the weight loss
group were on average heavier at the onset than women who
gained weight. Most women were parous at recruitment (80.7%)
and 12.4% had a family history of breast cancer. The age-specific
weight change variables were available for 5–14 cohorts per
variable, representing weight change over median time intervals
of 6.1–28.2 years and median follow-up for breast cancer of
4.2–17.2 years (Supporting Information Tables S1 and S2). For
all follow-up periods, the majority (80.3–90.4%) of women
gained weight.
Figure 1 shows HRs in relation to weight change without
(left) and with (right) adjustment for starting weight. There
was an inverse U-shaped association with risk (Fig. 1 and
Supporting Information Fig. S3, left), with women who lost
weight and those who gained weight since age 18–24 having
lower HRs than women whose weight remained constant
(within 5.0 kg). Women who lost ≥5 kg since ages
18–24 years had a statistically significantly lower breast cancer
risk than those whose weight remained constant. However,
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after additionally adjusting for starting weight (Figure 1 and
Supporting Information Fig. S3, right), which was on average
greater for women with weight loss than for those who gained
weight, the inverse HRs for weight loss were attenuated and no
longer associated with risk.
Weight gain from ages 18–24 to 35–44 years or from ages
18–24 to 45–54 years was associated with lower breast cancer risk,
although HRs were somewhat attenuated with adjustment for
starting weight. Linear inverse trends in risk per 5 kg gain over
these time periods remained statistically significant (HRs: 0.97,
95% CI: 0.96–0.98 for ages 18–24 to 35–44 and 0.96, 95% CI:
0.95–0.98 for 18–24 to 45–54 years). The association of starting
weight with risk remained statistically significant in these models
(data not shown).
Patterns of risk with weight change from later ages
(i.e. from 25 to 34 or 35–44 years) were less clear, with no
association between weight loss and linear trends with weight
gain not being statistically significantly associated with risk
after adjustment for starting weight.
In analyses by breast cancer invasiveness, the inverse asso-
ciations of weight gain with breast cancer risk tended to be
stronger for in situ than for invasive breast cancer, but only
significantly so for weight gain between ages 18–24 and
25–34 years (p-interaction = 0.007) (Supporting Information
Table S3). Stronger associations for in situ than invasive breast
cancer were also observed when we repeated the analyses
among subjects with a previous history of mammographic
screening only (data not shown).
Associations of weight gain from young ages tended to be
stronger for ER-positive than ER-negative (Table 2) or for ER
+/PR+ than ER− and PR− breast cancer (Supporting Infor-
mation Table S4). The differences in hazard ratios between
these subgroups were only strongly statistically significant for
one weight change group, however.
In analysis by breast cancer intrinsic subtype, weight gain
from ages 18–24 onwards was inversely associated with Lumi-
nal A-like (ER+ PR+ HER2−) breast cancer and weight gain
from ages 18–24 to 35–44 and to 45–54 years additionally
Table 1. Characteristics of women included in the analyses, by degree of weight change between the earliest available weight and weight at or
close to recruitment to the study
Factor1
Weight change category2
OverallLoss ≥5 kg
Stable
(4.9 kg)
Gain
5–9.9 kg
Gain
10–14.9 kg
Gain
15–19.9 kg
Gain
≥20 kg
Height (cm) Mean 165.0 164.4 164.9 165.0 165.2 165.6 164.8
Age at first weight3 Mean 19.9 22.1 20.1 19.5 19.3 19.1 20.6
First weight (kg) Mean 71.4 57.5 56.4 56.7 57.8 60.5 58.2
First BMI (kg/m2) Mean 26.2 21.3 20.7 20.8 21.2 22.0 21.4
Age at recruitment (years) Mean 37.9 37.6 38.8 39.8 40.2 40.4 39.3
Recruitment weight (kg) Mean 60.6 58.5 63.6 68.8 74.8 89.2 65.7
Recruitment BMI (kg/m2) Mean 22.2 21.7 23.4 25.3 27.4 32.5 24.2
Change in weight between
starting age and
recruitment (kg)
Mean −10.8 1.0 7.2 12.1 17.0 28.7 7.5
Median −8.7 1.4 7.0 12.0 17.0 26.0 5.9
Rate of weight change
between starting age
and recruitment (kg/year)
Mean −0.8 0.1 0.5 0.7 0.9 1.5 0.4
Median −0.5 0.1 0.4 0.6 0.8 1.3 0.3
Ethnicity
White % 90.0 90.4 87.7 84.4 79.6 70.5 85.7
Black % 6.0 5.3 8.6 12.3 17.5 27.3 10.6
Asian % 1.9 2.8 2.1 1.8 1.2 0.5 2.0
Other % 2.1 1.6 1.6 1.6 1.7 1.7 1.6
Continent of residence
North America % 63.2 57.4 53.2 51.6 55.0 65.6 56.6
Europe % 35.3 40.8 44.9 46.1 42.6 32.1 41.4
Australia % 0.8 0.7 1.3 1.8 2.2 2.2 1.3
Asia % 0.7 1.1 0.7 0.5 0.3 0.09 0.7
All participants Total 32,726 253,164 140,227 86,632 48,297 67,417 628,463
1Frequency distributions for nonmissing values only.
2Weight change was computed between earliest available weight and first weight available at or after recruitment, with the exception of a small number
of subjects for whom weight change was computed from two retrospectively assessed weights before recruitment because weight at or after recruitment
was not available.
3Weight was retrospectively assessed at age 18 or 20 for the majority of studies.
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with luminal B-like (other ER+/PR+) breast cancer risk
(Supporting Information Fig. S4). For some of the age groups,
there was evidence of a positive association with nonluminal
(ER− PR−) breast cancer risk, in particular, HER2-enriched
breast cancer, whereas there was no association with triple-
negative breast cancer risk.
There was evidence for effect modification by starting
weight for the linear effect of weight change at two age
groups, ages 18–24 to 45–54 years (p-interaction = 0.02) and
25–34 to 35–44 years (p-interaction = 0.006), but in opposite
directions and some of the results were based on small num-
bers of cases (Supporting Information Table S5). We observed
no statistically significant evidence for effect modification in
the linear association of weight change with risk by other
breast cancer risk factors considered (childhood body shape,
adult height, age at menarche, parity, age at first birth, num-
ber of births, family history of breast cancer and ethnicity, see
Supporting Information Table S6) or by time since weight
change (Supporting Information Table S7).
The main findings did not materially differ in the sensitivity
analyses conducted (see methods and Supporting Information
Tables S8 and S9 for selected results) except that the inverse
associations with weight gain were somewhat stronger when a
stricter definition of menopausal status was applied. When ana-
lysing risk in relation to average annual weight change, rather
than absolute amount of weight change, conclusions were
Ages 18−24 to 25−34
Lost ≥5.0 kg
+−4.9 kg
5.0−9.9 kg
10.0−14.9 kg
15.0−19.9 kg
≥20.0 kg
Trend per 5 kg weight gain
Ages 18−24 to 35−44
Lost ≥5.0 kg
±4.9 kg
5.0−9.9 kg
10.0−14.9 kg
15.0−19.9 kg
≥20.0 kg
Trend per 5 kg weight gain
Ages 18−24 to 45−54
Lost ≥5.0 kg
±4.9 kg
5.0−9.9 kg
10.0−14.9 kg
15.0−19.9 kg
≥20.0 kg
Trend per 5 kg weight gain
Ages 25−34 to 35−44
Lost ≥5.0 kg
±4.9 kg
5.0−9.9 kg
10.0−14.9 kg
15.0−19.9 kg
≥20.0 kg
Trend per 5 kg weight gain
Ages 25−34 to 45−54
Lost ≥5.0 kg
±4.9 kg
5.0−9.9 kg
10.0−14.9 kg
15.0−19.9 kg
≥20.0 kg
Trend per 5 kg weight gain
Ages 35−44 to 45−54
Lost ≥5.0 kg
±4.9 kg
5.0−9.9 kg
10.0−14.9 kg
15.0−19.9 kg
≥20.0 kg
Trend per 5 kg weight gain
occurred and weight change
Ages over which weight change
195
1730
789
412
205
254
2921
311
2981
1945
1178
659
964
6954
124
1092
898
745
445
769
3653
119
1874
523
220
81
76
2327
33
417
333
172
87
105
1042
164
2540
858
388
166
135
3555
cases
No. of
0.83 (0.72−0.96)
1.00 (ref)
0.98 (0.90−1.07)
0.97 (0.87−1.08)
0.90 (0.78−1.05)
0.80 (0.70−0.92)
0.96 (0.94−0.99)
0.74 (0.66−0.83)
1.00 (ref)
1.01 (0.95−1.07)
0.95 (0.89−1.02)
0.90 (0.82−0.98)
0.82 (0.76−0.88)
0.96 (0.95−0.97)
0.77 (0.64−0.93)
1.00 (ref)
1.01 (0.92−1.10)
1.00 (0.91−1.10)
0.89 (0.80−1.00)
0.80 (0.72−0.88)
0.96 (0.94−0.97)
0.86 (0.72−1.04)
1.00 (ref)
0.95 (0.86−1.04)
0.91 (0.79−1.05)
0.77 (0.61−0.96)
0.78 (0.62−0.99)
0.94 (0.91−0.98)
1.06 (0.74−1.51)
1.00 (ref)
1.11 (0.96−1.28)
0.92 (0.77−1.10)
0.85 (0.67−1.07)
0.88 (0.71−1.09)
0.96 (0.92−0.99)
0.92 (0.78−1.08)
1.00 (ref)
0.95 (0.88−1.03)
1.00 (0.89−1.11)
1.00 (0.85−1.17)
0.83 (0.70−0.99)
0.97 (0.94−0.99)
HRa (95% CI)Adjusted for covariatesa
0.5 1.0 2.0
HRa (95% CI)
1.09 (0.93−1.27)
1.00 (ref)
0.96 (0.88−1.04)
0.97 (0.87−1.08)
0.93 (0.80−1.08)
0.88 (0.77−1.02)
0.98 (0.96−1.01)
0.92 (0.81−1.04)
1.00 (ref)
0.98 (0.93−1.04)
0.93 (0.87−0.99)
0.89 (0.82−0.97)
0.85 (0.79−0.92)
0.97 (0.96−0.98)
0.95 (0.78−1.15)
1.00 (ref)
0.97 (0.89−1.06)
0.96 (0.87−1.06)
0.86 (0.77−0.96)
0.80 (0.73−0.88)
0.96 (0.95−0.98)
1.00 (0.83−1.21)
1.00 (ref)
0.97 (0.88−1.07)
0.96 (0.83−1.11)
0.83 (0.66−1.04)
0.86 (0.68−1.09)
0.97 (0.93−1.00)
1.31 (0.91−1.90)
1.00 (ref)
1.11 (0.96−1.29)
0.95 (0.79−1.14)
0.90 (0.71−1.14)
0.97 (0.78−1.22)
0.97 (0.93−1.01)
1.11 (0.94−1.31)
1.00 (ref)
0.97 (0.90−1.05)
1.05 (0.94−1.17)
1.08 (0.92−1.26)
0.92 (0.77−1.10)
0.99 (0.96−1.02)
HRb (95% CI)
Adjusted for covariates
and starting weightb
0.5 1.0 2.0
HRb (95% CI)
Figure 1. Relative risk of premenopausal breast cancer in relation to weight change between various ages. Abbreviations: HR, hazard ratio; CI,
confidence interval. (a) Adjusted for attained age, cohort, year of birth, adult height, age at menarche, age at first birth, number of births,
time since last birth and family history of breast cancer. (b) Adjusted for covariates in (a) plus weight at start of age range.
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similar, with the strongest inverse association with risk
observed for weight change over the longest interval, from ages
18–24 to 45–54 years (HR = 0.82, 95% CI: 0.75–0.89 per
kg/year), reflecting the largest absolute weight gains
(Supporting Information Fig. S5).
Discussion
We observed that both weight loss ≥5 kg and weight gain of
≥10–15 kg since early adulthood were inversely associated
with premenopausal breast cancer risk, but that degree of
weight change was associated with initial weight, and that
only weight gain was associated with risk after controlling for
early adult weight. Early-adulthood weight remained signifi-
cant in such models, indicating that both starting weight and
weight gain are associated with risk. There was weak and
inconsistent evidence that the effect of weight gain depended
on starting weight, and no evidence that the association varied
by other investigated breast cancer risk factors. We captured
weight change between ages 18–24 and 35–44 years, when
most parous women had their pregnancies, but did not find
statistical evidence that the association of weight change with
risk differed between parous and nulliparous women. Weight
change from later ages, age 35 years onwards, was not associ-
ated with risk.
Our pooling project incorporates data from most,15–22
although not all,23–28 published prospective studies on long-
term weight change and premenopausal breast cancer risk,
and additionally include previously unpublished data. It con-
sequently had enhanced statistical power based on its large
sample size. Few past studies reported on weight loss sepa-
rately; those that did reported null associations or nonsignifi-
cant inverse associations with weight loss since age 18 or
20 years compared with women whose weight remained
stable,15,21–23,26 and not all adjusted for starting weight. In
relation to weight gain, the majority of prospective studies
have reported null or nonstatistically significant inverse linear
trends,15,18–28 except for two reporting positive associations,
but with no clear dose–response relationship.16,20
There was a tendency for inverse associations with risk to
be somewhat stronger for in situ than invasive breast cancer;
this might reflect stage-specific aetiology or could be
artefactual, for example, a deficit of in situ diagnoses could
occur if increasing weight made women less likely to attend
breast screening or if they presented later because breast self-
examination and lump detection is more difficult.29 Stronger
associations for in situ than invasive cancer were also
observed among women who had previously had a screening
mammogram, suggesting that it is not explained by past
breast screening attendance, but unfortunately we did not
have data on mode of detection of breast cancer.
In analyses by ER-status, we observed inverse associations
of weight gain with ER+, but not with PR–breast cancer. This
agrees with our previous finding that BMI at ages over 25 years
is inversely associated with risk of hormone-receptor-positiveTa
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breast cancer only.4 In augmentation analyses by intrinsic sub-
type, however, we observed somewhat contradictory findings,
with some weight change variables being positively associated
with HER2-enriched breast cancer and nonluminal breast can-
cer overall. These analyses were conducted on somewhat dif-
ferent subsets of the data and some of them on small numbers.
Whether there is an association of weight change with non-
luminal subtypes remains therefore uncertain.
It is of interest that we observed the strongest inverse asso-
ciations with risk for weight change from early adulthood and
no significant association of risk with absolute or rate of
weight gain from ages 35–44 years onwards. Weight gain
soon after age 18, if not followed by later weight loss, would
lead to the greatest cumulative exposure to adiposity. It is
possible that it is cumulative exposure to excess weight that is
inversely associated with risk or that late weight gain is out-
side the susceptibility window for premenopausal breast can-
cer, for example, because there is a lag time between weight
gain and an effect on risk. Our analyses by time since weight
gain did not suggest the latter is the case. The lack of associa-
tion with later (i.e. ≥35 years) weight gain appears discordant
with the results from two previous studies. The EPIC-
PANACEA study reported a positive association of rate of
weight gain over 4 years with breast cancer diagnosed at age
≤50 years, based on 283 cases.30 Women were premenopausal
at study entry (median age 40.7 years, M. Emaus, personal
communication) but no information on menopausal status at
the second weight assessment or at diagnosis was available; it
is therefore possible that some of the women were postmeno-
pausal at diagnosis. The Nurses’ Health Study reported a pos-
itive association of weight gain over 4 years among initially
premenopausal women with breast cancer risk over the subse-
quent 2 years (HR: 1.38, 95% CI: 1.13–1.69 for ≥15 vs. <5 lbs,
n = 736 cases).31 In our study, weight change was assessed
over longer periods but the reason for the disparity in results
is unclear.
The strong inverse association of breast cancer risk with
early adult body size4 may originate in early life, or in child-
hood/adolescence.5,6 It has been hypothesised to be due to
greater differentiation of breast tissue during puberty,2,32
altered oestrogen metabolism,33 lower adult mammographic
density34,35 and/or lower circulating IGF-I levels36 in heavier
girls. Additional weight gain is associated with a reduction in
mammographic density37 and substantial weight gain leading
to obesity suppresses ovarian function,38,39 with a consequent
reduction in endogenous sex hormone, in particular, proges-
terone, exposure.38 Weight gain might affect risk through
changes in hormone profile because young women with high
BMI have been reported to have lower levels of sex-hormone-
binding globulin (SHBG), oestradiol and progesterone, and
higher levels of free testosterone than women with lower
BMI.40 Oestrogens and testosterone have been associated with
premenopausal breast cancer risk,41 although less clearly than
for postmenopausal breast cancer, but the evidence for an
association of risk with progesterone is inconsistent, how-
ever.41 A recent study reported lower breast cell proliferation
in heavier compared with leaner premenopausal women, and
the reverse in postmenopausal women, which might be
hormone-related.42
Strengths of our study include its prospective design, its
large number of cases, and therefore its ability to investigate
associations according to breast cancer characteristics, multi-
ple time-points of weight assessments, and the use of time-
updated covariates. Limitations include that weight at ages
18–24 years was ascertained by recall for most participants,
but recalled weight at age 18 years has been shown to corre-
late well with measured weight,43 and that we did not consider
central adiposity measures. We studied weight change over
six, some overlapping, age categories, using data of somewhat
different populations, but a sensitivity analyses restricting to
the five cohorts that contributed to all age categories showed
similar results. There were too few women contributing to
consecutive nonoverlapping time periods of weight change to
investigate the role timing of weight change in a single model.
In analyses by breast cancer subtype, numbers of subtype-
specific breast cancers were modest for some of the weight
change variables. Furthermore, our data set was not well-
suited to investigate Asian women. We did not observe effect
modification by ethnicity, but the study included relatively
few women of Asian descent. It has been suggested that
among Asian women, there is a positive association between
BMI and premenopausal breast cancer risk,44 but prospective
studies of weight gain in Asian women have, so far, shown an
inverse or null association with premenopausal breast cancer
risk overall.24,26,45
Our results may contribute to the understanding of breast
cancer causation and aid in risk stratification. However,
weight gain would not provide a strategy for long-term risk
reduction because weight and weight gain are positively asso-
ciated with risks of postmenopausal breast cancer, several
other types of cancer, and other adverse health outcomes.46,47
Additionally, obese women diagnosed with breast cancer tend
to have worse outcomes than leaner women, independent of
their menopausal status.48
In conclusion, we have observed that both body size in
early adulthood and subsequent weight gain are independently
associated with reductions in premenopausal breast cancer
risk. There is a need to understand mechanisms underlying
this finding, which may provide a means for breast cancer
prevention.
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